Breaking News
March 21, 2019 - Mutations in noncoding genes could play big role in regulating cancer, study finds
March 21, 2019 - A medical student’s thoughts on Match Day
March 21, 2019 - Are eggs good or bad for you?
March 21, 2019 - New analysis reveals precision oncology insights for colorectal cancer
March 21, 2019 - Pollutants appear to weaken immune system and increase pathogen virulence
March 21, 2019 - Researchers develop and validate scale for rating severity of mononucleosis
March 21, 2019 - Scientists identify generation of key immune response in mice on introducing solid food
March 21, 2019 - New nanomaterial could restore internal structure of damaged bones
March 21, 2019 - Selective destruction of prostate tumor as effective as complete prostate removal
March 21, 2019 - 2011 to 2015 Saw Increase in Psychiatric ED Visits for Youth
March 21, 2019 - Tapeworm drug targets common vulnerability in tumor cells
March 21, 2019 - Off the beaten path for global health residency
March 21, 2019 - European Parliament’s report calls on EU to develop policies to regulate endocrine-disrupting chemicals
March 21, 2019 - Women with undiagnosed diabetes in pregnancy more likely to experience stillbirths
March 21, 2019 - Fish consumption can help prevent asthma, study reveals
March 21, 2019 - Royal Holloway professors to lead new to research into curing Neurofibromatosis type 1
March 21, 2019 - NSF offers grant to improve treatment approaches for pelvic organ prolapse
March 21, 2019 - Your Apple Watch Might Help Spot a Dangerous Irregular Heartbeat
March 21, 2019 - Research team uncovers critical new clues about what goes awry in autistic brains
March 21, 2019 - From March Madness to medicine with help from mentors
March 21, 2019 - Mental health disorders among young adults may be on the increase
March 21, 2019 - New study examines smarter automatic defibrillator
March 21, 2019 - UC Riverside research shows how natural selection favors cheaters
March 21, 2019 - Mother’s diet during pregnancy can impact lung-specific genes of her offspring
March 21, 2019 - AeroForm Tissue Expanders makes breast reconstruction after mastectomy more comfortable
March 21, 2019 - New project focuses on creating more responsive, intuitive prosthetics
March 21, 2019 - New case study describes adolescent patient with rapid-onset schizophrenia and Bartonella infection
March 21, 2019 - Umass Amherst food scientist honored with 2019 Young Scientist Research Award
March 21, 2019 - Smell of skin could lead to early diagnosis for Parkinson’s
March 21, 2019 - Difference in brain connectivity may explain autism spectrum disorder
March 21, 2019 - Untangling the microbiome — with statistics
March 21, 2019 - Human microbiome metabolites enhance colon injury by enterohemorrhagic E. coli, study shows
March 21, 2019 - Written media can improve citizens’ understanding of palliative care
March 21, 2019 - New research aims to find how asthma symptoms are aggravated
March 21, 2019 - New $9.7 million NIH grant project seeks to improve hearing restoration
March 21, 2019 - Researchers measure brain metabolite levels in people with mild memory problems
March 21, 2019 - FDA approves first drug for treatment of postpartum depression in adult women
March 20, 2019 - Gene editing and designer babies experiments face global moratorium
March 20, 2019 - Major scientific study of wound care dressings wins ‘Best Clinical or Preclinical Research Award’
March 20, 2019 - Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
March 20, 2019 - Big data study identifies drugs that increase risk of psychosis in youth with ADHD
March 20, 2019 - Mystery novel and dream spur key scientific insight into heart defect | News Center
March 20, 2019 - Study measures impact of policies designed to reduce air pollution in two mega-cities
March 20, 2019 - Mild sleep apnea during pregnancy changes sugar levels and may affect infant growth patterns
March 20, 2019 - SSB and Novasep collaborate to develop new membrane chromatography systems
March 20, 2019 - Leaky valve repair improves quality of life in heart failure patients
March 20, 2019 - Diattenuation Imaging offers structural information of difficult to access brain regions
March 20, 2019 - Early sports specialization linked to increased injury rates during athletic career
March 20, 2019 - Study brings clarity about milk intake for children with Duarte galactosemia
March 20, 2019 - Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
March 20, 2019 - Maternal smoking during pregnancy increases risk of ADHD among offspring up to three-fold
March 20, 2019 - Pioneering pediatric kidney transplant surgeon Oscar Salvatierra dies at 83 | News Center
March 20, 2019 - F.D.A. Approves First Drug for Postpartum Depression
March 20, 2019 - TB remains a major public health challenge in the European region
March 20, 2019 - Most pills contain common allergens, warn experts
March 20, 2019 - Researchers discover previously unknown mechanism by which cells can sense oxygen
March 20, 2019 - World’s leading source of data on diagnosis, treatments for aortic dissection
March 20, 2019 - Breast cancer relapse predictor may soon be a reality
March 20, 2019 - Researchers identify origin of chronic pain in humans
March 20, 2019 - Two-drug combinations containing calcium channel blocker significantly lowers BP
March 20, 2019 - King’s scientists to monitor air quality exposure of 250 children
March 20, 2019 - Active substance from plant could turn into a ray of hope against eye tumors
March 20, 2019 - Preventative cardioverter defibrillator implantation is of little benefit to kidney dialysis patients
March 20, 2019 - New method based on neurofeedback may reduce anxiety
March 20, 2019 - Study explores whether alcohol consumption can have an effect on arthritis
March 20, 2019 - Merck to collaborate with GenScript for plasmid and virus manufacturing in China
March 20, 2019 - FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression
March 20, 2019 - Study examines long-term opioid use in patients with severe osteoarthritis
March 20, 2019 - Retired Stanford professor Edward Rubenstein, pioneer in intensive care medicine, dies at 94 | News Center
March 20, 2019 - Aaron Diamond AIDS Research Center to Join Columbia University
March 20, 2019 - Call for halt to human gene editing and designer babies experiments
March 20, 2019 - Study illuminates how hot spots of genetic variation evolved in the human genome
March 20, 2019 - Roundworm study suggests alternatives for treatment of schizophrenia
March 20, 2019 - Sphingotec reports new applications of bio-ADM at 39th ISICEM
March 20, 2019 - Preventing falls through free community-based screenings for older adults
March 20, 2019 - AAOS: Supplement Use Low in Patients With Osteoporosis, Hip Fracture
March 20, 2019 - Does intensive blood pressure control reduce dementia?
March 20, 2019 - Nut consumption could be key to better cognitive health in older people
March 20, 2019 - Drinking hot tea associated with increased risk of esophageal cancer
March 20, 2019 - Androgen receptor plays vital role in regulating multiple mitochondrial processes
Gene Therapy Offers Hope for Inherited Retinal Disorder

Gene Therapy Offers Hope for Inherited Retinal Disorder

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • Patients with inherited retinal disease due to biallelic mutation in the RPE65 gene had sustained functional vision improvement when treated with voretigene neparvovec (Luxturna), according to a phase III study in 29 patients.
  • Note that RPE65 is an isomerohydrolase enzyme (expressed in the retinal pigment epithelium) that converts vitamin A from an inactive to an active form, and is responsible for rod and cone functioning.

NEW ORLEANS — Gene augmentation by voretigene neparvovec (Luxturna) improves functional vision in patients with biallelic mutation in the RPE65 gene, a mutation that results in inherited retinal disease, researchers reported here.

Twenty seven of 29 (93%) of patients with Leber congenital amaurosis (LCA) who were treated with the investigational gene therapy had their vision improved to the degree that they could navigate a maze in low to moderate light. They also demonstrated improvement in light sensitivity and peripheral vision, according to Stephen R. Russell, MD, of the University of Iowa in Iowa City, and colleagues.

The improvement was maintained to 3 years, according to updated data from a phase III study presented at the American Academy of Ophthalmology (AAO) meeting.

In October, an FDA advisory committee unanimously recommended approval of the gene treatment for patients with vision loss due to confirmed biallelic RPEmutation-associated retinal dystrophy. The FDA is expected to render a decision no later than January 2018.

“So far, we have followed patients for up to 4 years, and have not seen any significant drop-off,” Russell said at an AAO, press briefing. “We will be observing these patients up to 15 years by FDA protocol.”

RPE65 is an isomerohydrolase enzyme expressed in the retinal pigment epithelium; this enzyme converts vitamin A from an inactive to an active form. The expression of the RPE65 gene is responsible for rod and cone functioning. Autosomal-recessive mutations in the RPE65 gene result in difficulty in navigating unfamiliar environments, night blindness, loss of visual acuity, and a progressive loss of the visual field.

The effect of noretigene neparvovec was studied in a 1-year open-label, randomized, controlled study period, after which patients in the control group could cross over to active treatment. The treatment was delivered bilaterally, 6 to 18 days apart.

The 31 patients, ages 4 to 44 years at the time of treatment, were randomized in a 2:1 ratio to treatment (n=21) or control (n=10).

The primary endpoint was the change in bilateral performance in the multi-luminance mobility test (MLMT), an endpoint designed specifically for LCA, at 1 year. The MLMT measures functional performance through navigation of a mobility course in which participants follow arrows and avoid obstacles. The test was conducted at various light levels, ranging from 1 to 400 lux. The course navigation was captured on video and graded for accuracy and time.

At 1 year, per the mean change in the bilateral MLMT score differed by 1.6 in favor of the active treatment (95% CI 0.72-2.41, P=0.0013). Those who received gene therapy also showed a marked improvement compared with controls in full-field light sensitivity (FST) threshold testing averaged over both eyes (P=0.0004) and MLMT change score for the first injected eye (P=0.0005).

However, the change in visual acuity averaged over both eyes was not significantly different between intervention and control patients (P=0.17).

The mean bilateral MLMT score change at 3 years for 20 patients originally randomized to gene augmentation was 1.8. In nine patients who crossed over, the mean bilateral score change was 2.1 relative to injection baseline after year 1.

Similarly, the mean change from baseline in white light FST was 2.04 at year 3 in 19 participants who received noretigene neparvovec. This same score improved by 2.69 at year 2 in the nine patients who crossed over.

The change in mean visual acuity score was consistent through year 2 for the crossover population and through year 3 in the population originally randomized to noretigene neparvovec. “We have a very small population, so there’s a lot of variability,” Russell stated.

“There were no serious ocular surgery concerns,” he said. “The complications that we saw were largely related to the procedure of placing the subretinal gene therapy as opposed to agent-related reactions.”

Ten patients (17%) had cataracts and three (10%) had intraoperative retinal tears that were treated at the time of gene therapy. Three patients (10%) had retinal deposits.

Irene Maumenee, MD, of the Ocular Genetics Laboratory at the University of Illinois in Chicago, said the results represent the beginning of a treatment wave of genetic eye disease, with further improvements down the road. She cautioned that it may be premature to treat without a full understanding of the variation in disease that occurs with mutation in the same gene.

“Has there ever been any treatment where the dosage was right from the beginning?” she stated. “Probably not. So if this is the first wave of treatment that would be 100% correct, [that ] is … maybe presumptuous. There are so many problems to overcome from the beginning.” Maumenee was not involved in the study.

Russell disclosed a relevant relationship with Spark Therapeutics.

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles